Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stacy

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Parkinsonism & Related Disorders|December 18, 2007
Apomorphine for the acute treatment of "off" episodes in Parkinson's diseaseMark Stacy, Dee Silver
Clinical Neuropharmacology|April 3, 2008
Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesiaMark Stacy, Andrew Galbreath
Parkinson'S Disease|May 24, 2011
Dopamine-induced nonmotor symptoms of Parkinson's diseaseAriane Park, Mark Stacy
Expert Opinion on Pharmacotherapy|December 14, 2011
Istradefylline for the treatment of Parkinson's diseaseAriane Park, Mark Stacy
Drugs|November 20, 2015
Disease-Modifying Drugs in Parkinson's DiseaseAriane Park, Mark Stacy
Drug Design, Development and Therapy|May 25, 2011
Available and emerging treatments for Parkinson's disease: a reviewPatrick Hickey, Mark Stacy
Journal of Neurology|August 28, 2009
Non-motor symptoms in Parkinson's diseaseAriane Park, Mark Stacy
Clinical Neuropharmacology|February 28, 2008
Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesiaMark Stacy, Andrew Galbreath
Expert Opinion on Biological Therapy|December 12, 2012
AAV2-neurturin (CERE-120) for Parkinson's diseasePatrick Hickey, Mark Stacy
CNS Drugs|July 17, 2007
Medical management of levodopa-associated motor complications in patients with Parkinson's diseaseJoseph Jankovic, Mark Stacy
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Parkinsonism & Related Disorders|December 18, 2007
Apomorphine for the acute treatment of "off" episodes in Parkinson's diseaseMark Stacy, Dee Silver
Clinical Neuropharmacology|April 3, 2008
Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesiaMark Stacy, Andrew Galbreath
Parkinson'S Disease|May 24, 2011
Dopamine-induced nonmotor symptoms of Parkinson's diseaseAriane Park, Mark Stacy
Expert Opinion on Pharmacotherapy|December 14, 2011
Istradefylline for the treatment of Parkinson's diseaseAriane Park, Mark Stacy
Drugs|November 20, 2015
Disease-Modifying Drugs in Parkinson's DiseaseAriane Park, Mark Stacy
Drug Design, Development and Therapy|May 25, 2011
Available and emerging treatments for Parkinson's disease: a reviewPatrick Hickey, Mark Stacy
Journal of Neurology|August 28, 2009
Non-motor symptoms in Parkinson's diseaseAriane Park, Mark Stacy
Clinical Neuropharmacology|February 28, 2008
Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesiaMark Stacy, Andrew Galbreath
Expert Opinion on Biological Therapy|December 12, 2012
AAV2-neurturin (CERE-120) for Parkinson's diseasePatrick Hickey, Mark Stacy
CNS Drugs|July 17, 2007
Medical management of levodopa-associated motor complications in patients with Parkinson's diseaseJoseph Jankovic, Mark Stacy
Pageof 7